SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30,
2024 /PRNewswire/ -- Duality Biologics ("DualityBio")
announced that, BeiGene. Ltd. has exercised its exclusive option
for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from
DualityBio, securing global development, manufacturing, and
commercialization rights for the investigational product. In 2024,
DualityBio received an option exercise fee and a milestone payment
based on the Phase I dose-escalation advancement.
In July 2023, DualityBio announced
an agreement for BeiGene to acquire its exclusive option for a
global clinical and commercial license to an investigational,
preclinical ADC therapy for patients with select solid tumors.
Under the terms of the agreement, DualityBio received an upfront
payment, and is eligible for a payment contingent upon BeiGene
exercising its option and additional payments based upon the
achievement of certain development, regulatory, and commercial
milestones, totaling up to $1.3
billion, in addition to tiered royalties.
About DualityBio
Duality Biologics is a
clinical-stage biotech company dedicated to the discovery and
development of next-generation ADC to treat cancer and autoimmune
diseases. DualityBio has successfully built several cutting-edge
ADC technology platforms with global intellectual property rights.
Leveraging a robust pipeline, DualityBio is conducting multiple
global clinical trials across 17 countries, has enrolled over 1,500
patients for multiple clinical-stage ADC candidates.
Additionally, DualityBio have established strategic
collaborations with global MNCs and leading biotech innovators. As
a global ADC powerhouse, DualityBio is developing
"Super ADCs," including bispecific ADCs, novel-payload ADCs, and
autoimmune ADCs. For more information, please visit
www.dualitybiologics.com.
Media
Contact
PR@dualitybiologics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/duality-biologics-announces-b7h4-adc-milestone-achievement-and-license-exercise-by-beigene-302340165.html
SOURCE Duality Biologics
